Systemic Lupus Erythematosus Market | SLE Market | Epidemiology, Treatment, Pipeline Scenario (2017-30)

Systemic Lupus Erythematosus Market | SLE Market | Epidemiology, Treatment, Pipeline Scenario (2017-30)

“Systemic Lupus Erythematosus Market | SLE Market”
DelveInsight’s “Systemic Lupus Erythematosus Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Systemic Lupus Erythematosus, historical and forecasted epidemiology as well as the Systemic Lupus Erythematosus market trends in the 7MM.
According to DelveInsight, Systemic Lupus Erythematosus market in 7MM is expected to change in the study period 2017-2030.

DelveInsight’s “Systemic Lupus Erythematosus Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Systemic Lupus Erythematosus, historical and forecasted epidemiology as well as the Systemic Lupus Erythematosus market trends in the 7MM.

Systemic Lupus Erythematosus (SLE) is a systemic autoimmune disease. The disease has a highly variable course and prognosis. The term lupus has been used to identify a number of chronic, autoimmune diseases that can damage any part of the body (such as skin, joints, and/or organs inside the body).

The Systemic Lupus Erythematosus market report provides current treatment practices, emerging drugs, Systemic Lupus Erythematosus market share of the individual therapies, current and forecasted Systemic Lupus Erythematosus Market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Systemic Lupus Erythematosus treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Systemic Lupus Erythematosus Epidemiology

The Systemic Lupus Erythematosus epidemiology division provide insights about historical and current Systemic Lupus Erythematosus patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 

As per DelveInsight estimates, total diagnosed prevalent cases of SLE in the 7MM was found to be 484,213 in 2017. Among all the countries, the estimates show higher population of SLE in the United States with 259,474 cases in 2017.

Systemic Lupus Erythematosus Epidemiology Segmentation

The epidemiology segment also provides the Systemic Lupus Erythematosus epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

  • Total Diagnosed Prevalent cases of SLE in 7MM
  • Gender-Specific cases of SLE in 7 MM
  • Severity-Specific cases of SLE in 7MM
  • Treatable cases of SLE in 7MM

 

Systemic Lupus Erythematosus Market Outlook

The Systemic Lupus Erythematosus market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Systemic Lupus Erythematosus market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

The current market of SLE is majorly driven by Corticosteroids, Immunosuppressants, Antimalarials (Plaquenil) and Biologics (Rituximab, Belimumab). Nonsteroidal anti- inflammatory drugs (NSAIDs) may also be used to treat inflammation and pain.

Among these, Hydroxychloroquine (Plaquenil) and Belimumab (Benlysta) are approved therapies for the treatment of SLE in the US.

Anifrolumab (AstraZeneca), Lupuzor (ImmuPharma), Baricitinib (Eli Lilly), Stelara (Janssen Pharmaceutical), Atacicept (Merck KGaA), ILT-101 (ILTOO Pharma), BIIB059 (Biogen), CC-220 (Celgene), Dapirolizumab pegol (UCB Pharma/Biogen), IFNα Kinoid (Neovacs), Cenerimod (Idorsia Pharmaceuticals), KZR-616 (Kezar Life Sciences), Lulizumab pegol (BristolMyers Squibb), XmAb5871 (Xencor),and others are currently under development for the treatment of SLE.

This segment gives a thorough detail of Systemic Lupus Erythematosus market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

Request for Sample Pages to know more.

According to DelveInsight, Systemic Lupus Erythematosus market in 7MM is expected to change in the study period 2017-2030.

Scope of the Report

  • The report covers the descriptive overview of Systemic Lupus Erythematosus, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Systemic Lupus Erythematosus epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Systemic Lupus Erythematosus are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Systemic Lupus Erythematosus market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Systemic Lupus Erythematosus market

 

Table of Contents

1. Key Insights

2. Executive Summary of Systemic Lupus Erythematosus

3. Competitive Intelligence Analysis for Systemic Lupus Erythematosus

4. Systemic Lupus Erythematosus: Market Overview at a Glance

5. Systemic Lupus Erythematosus: Disease Background and Overview

6. Patient Journey

7. Systemic Lupus Erythematosus Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Systemic Lupus Erythematosus Treatment

11. Marketed Products

12. Emerging Therapies

13. Systemic Lupus Erythematosus: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Systemic Lupus Erythematosus

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

*The table of contents is not exhaustive; the final content may vary. 

 

 

 

About DelveInsight

DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for better growth in the market.

Browse through our vast repository from here.

 

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Vinita Rakheja
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: www.delveinsight.com/